Despite some limitations, we have, for the first time, established TAB2-knockout iPSC-derived cardiomyocytes using CRISPR/Cas9, discovered a novel mechanism of TAB2-knockout DCM, and improved the phenotype by inhibiting RIPK1. The gene discussed is RIPK1; the disease is familial dilated cardiomyopathy.